perphenazine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
2113 58-39-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • perphenazine
  • perfenazine
  • perfenil
  • perphenan
  • perphenazin
  • thilatazin
  • tranquisan
  • perphanzine
An antipsychotic phenothiazine derivative with actions and uses similar to those of CHLORPROMAZINE.
  • Molecular weight: 403.97
  • Formula: C21H26ClN3OS
  • CLOGP: 4.01
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 1
  • TPSA: 29.95
  • ALOGS: -4.23
  • ROTB: 6
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
30 mg O
7 mg P
10 mg P
16 mg R

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.99 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 40 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 18 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 27 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.07 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 9.40 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 0.02 mg/mL Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 3.459 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.918 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 25.645 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 41.400 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 2.290 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 4.520 % High 1
herg hERG pIC50 5.930 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 28.907 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 58.614 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 1.610 % High 1
kinase-safety-class ACVR2A,ACVR2B,AKT1,AKT2,AKT3,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,CHEK1,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK2,JAK3,MAP3K21,MAP3K7,MAPK10,MAPK12,MAPK7,MAPK9,MAPKAPK2,MET,MTOR,NTRK2,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK 48
kinase-selectivity-class AXL,EPHB4,PDK4,SIK2 4
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 3.776 High 1
mh-clint Mouse hepatocyte intrinsic clearance 162.181 High 1
mppb Mouse plasma protein binding (% unbound) 2.550 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 9.376 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 7.490 % High 1
rh-clint Rat hepatocyte intrinsic clearance 254.097 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 14.920 % High 1
rppb Rat plasma protein binding (% unbound) 1.970 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 52.723 uM High 1

Approvals:

DateAgencyCompanyOrphan
Feb. 27, 1957 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Tardive dyskinesia 303.24 29.18 76 4280 10854 90613237
Dystonia 252.63 29.18 72 4284 16747 90607344
Parkinsonism 232.94 29.18 65 4291 14000 90610091
Dyskinesia 186.58 29.18 69 4287 36465 90587626
Myoclonus 167.08 29.18 54 4302 19114 90604977
Apraxia 155.84 29.18 33 4323 2229 90621862
Creatinine renal clearance increased 143.62 29.18 33 4323 3248 90620843
Renal function test abnormal 141.11 29.18 38 4318 7153 90616938
Drug abuse 135.56 29.18 70 4286 82277 90541814
Head titubation 125.55 29.18 25 4331 1243 90622848
Sedation complication 116.76 29.18 40 4316 16904 90607187
Creatinine renal clearance decreased 104.95 29.18 38 4318 18861 90605230
Multiple drug therapy 91.78 29.18 27 4329 6982 90617109
Sedation 91.05 29.18 45 4311 48126 90575965
Blood calcium decreased 87.70 29.18 38 4318 30144 90593947
Polydipsia 86.01 29.18 23 4333 4208 90619883
Orthostatic hypotension 81.80 29.18 40 4316 41787 90582304
Depressed level of consciousness 81.44 29.18 48 4308 72736 90551355
Blood magnesium increased 81.14 29.18 21 4335 3387 90620704
Pleural fibrosis 80.02 29.18 21 4335 3575 90620516
Presbyacusis 78.56 29.18 20 4336 3022 90621069
Overdose 78.34 29.18 63 4293 157646 90466445
Pleural thickening 77.26 29.18 20 4336 3228 90620863
Neuroleptic malignant syndrome 71.45 29.18 27 4329 15069 90609022
Hyperprolactinaemia 71.44 29.18 21 4335 5412 90618679
Movement disorder 66.63 29.18 31 4325 28988 90595103
Toxicity to various agents 66.04 29.18 75 4281 287771 90336320
Extrapyramidal disorder 65.91 29.18 26 4330 16277 90607814
Cognitive disorder 62.86 29.18 40 4316 69367 90554724
Deafness neurosensory 62.53 29.18 20 4336 6821 90617270
Drug interaction 61.66 29.18 71 4285 276382 90347709
Epigastric discomfort 60.55 29.18 20 4336 7548 90616543
Sopor 58.68 29.18 27 4329 24617 90599474
Balance disorder 48.61 29.18 39 4317 97041 90527050
Cyst 48.57 29.18 21 4335 16540 90607551
Blood potassium increased 44.04 29.18 21 4335 20728 90603363
Tremor 43.99 29.18 45 4311 153128 90470963
Mitochondrial encephalomyopathy 43.66 29.18 7 4349 98 90623993
Ileus paralytic 42.94 29.18 14 4342 5071 90619020
Osteopenia 41.98 29.18 21 4335 22981 90601110
Bone cyst 34.84 29.18 10 4346 2368 90621723
Hyponatraemia 34.34 29.18 37 4319 133501 90490590
Deformity 34.27 29.18 15 4341 12155 90611936
Osteosclerosis 32.89 29.18 11 4345 4309 90619782
Moaning 32.64 29.18 8 4348 1035 90623056
Hypotension 32.55 29.18 57 4299 325340 90298751
Skin lesion 32.48 29.18 21 4335 37344 90586747
Mobility decreased 30.54 29.18 48 4308 250686 90373405
Onychophagia 30.50 29.18 5 4351 81 90624010
Bladder disorder 29.44 29.18 13 4343 10759 90613332
Intentional self-injury 29.29 29.18 18 4338 29316 90594775

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Antipsychotic drug level below therapeutic 581.27 47.07 114 3356 3090 42614775
Akathisia 567.85 47.07 138 3332 10313 42607552
Therapeutic product effect variable 560.19 47.07 110 3360 2999 42614866
Disinhibition 559.06 47.07 114 3356 3781 42614084
Obsessive-compulsive disorder 539.95 47.07 122 3348 6621 42611244
Euphoric mood 512.55 47.07 116 3354 6337 42611528
Increased appetite 465.17 47.07 114 3356 8792 42609073
Suicide attempt 329.77 47.07 128 3342 45972 42571893
Leukaemia 261.45 47.07 66 3404 5706 42612159
Therapeutic product effect incomplete 224.50 47.07 111 3359 70828 42547037
Weight increased 212.22 47.07 123 3347 107860 42510005
Dyslipidaemia 211.66 47.07 62 3408 9356 42608509
Leukopenia 210.23 47.07 108 3362 74638 42543227
Toxicity to various agents 196.73 47.07 156 3314 228980 42388885
Obesity 173.77 47.07 61 3409 16398 42601467
Prescribed overdose 160.10 47.07 54 3416 12873 42604992
Schizoaffective disorder 116.82 47.07 28 3442 1942 42615923
Irritability 91.57 47.07 45 3425 28083 42589782
Neuroleptic malignant syndrome 77.87 47.07 37 3433 21435 42596430
Drug ineffective 75.03 47.07 160 3310 630037 41987828
Product use in unapproved indication 50.13 47.07 68 3402 184388 42433477
Hypertension 47.49 47.07 63 3407 167141 42450724

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Akathisia 226.74 30.71 69 6186 17044 110566000
Tardive dyskinesia 224.59 30.71 65 6190 13514 110569530
Antipsychotic drug level below therapeutic 200.64 30.71 40 6215 1695 110581349
Therapeutic product effect variable 188.32 30.71 41 6214 2677 110580367
Disinhibition 177.07 30.71 40 6215 3094 110579950
Dystonia 168.44 30.71 61 6194 25744 110557300
Parkinsonism 165.85 30.71 58 6197 22129 110560915
Obsessive-compulsive disorder 153.02 30.71 42 6213 7199 110575845
Euphoric mood 144.79 30.71 42 6213 8785 110574259
Creatinine renal clearance increased 134.97 30.71 33 6222 3592 110579452
Toxicity to various agents 134.62 30.71 150 6105 480405 110102639
Neuroleptic malignant syndrome 131.50 30.71 55 6200 34004 110549040
Dyskinesia 130.85 30.71 62 6193 51384 110531660
Renal function test abnormal 126.73 30.71 38 6217 8908 110574136
Apraxia 125.59 30.71 31 6224 3509 110579535
Head titubation 125.59 30.71 26 6229 1331 110581713
Dyslipidaemia 120.31 30.71 42 6213 15923 110567121
Increased appetite 115.16 30.71 40 6215 14937 110568107
Schizoaffective disorder 108.92 30.71 27 6228 3109 110579935
Sedation complication 107.75 30.71 41 6214 19814 110563230
Sedation 96.77 30.71 56 6199 69627 110513417
Creatinine renal clearance decreased 93.59 30.71 38 6217 21777 110561267
Hyperprolactinaemia 93.43 30.71 28 6227 6547 110576497
Drug abuse 88.26 30.71 76 6179 177335 110405709
Myoclonus 87.66 30.71 41 6214 32957 110550087
Blood calcium decreased 84.43 30.71 41 6214 35804 110547240
Multiple drug therapy 83.86 30.71 27 6228 7987 110575057
Irritability 78.79 30.71 43 6212 47766 110535278
Presbyacusis 76.83 30.71 20 6235 2799 110580245
Suicide attempt 76.57 30.71 56 6199 103338 110479706
Blood magnesium increased 75.35 30.71 21 6234 3802 110579242
Pleural thickening 73.12 30.71 20 6235 3379 110579665
Extrapyramidal disorder 70.94 30.71 34 6221 28833 110554211
Orthostatic hypotension 70.74 30.71 45 6210 66204 110516840
Polydipsia 68.75 30.71 23 6232 7665 110575379
Pleural fibrosis 68.43 30.71 20 6235 4288 110578756
Completed suicide 68.18 30.71 76 6179 242305 110340739
Leukaemia 65.28 30.71 22 6233 7496 110575548
Overdose 56.82 30.71 68 6187 233726 110349318
Depressed level of consciousness 55.58 30.71 48 6207 112230 110470814
Movement disorder 55.19 30.71 31 6224 36373 110546671
Epigastric discomfort 53.93 30.71 20 6235 8995 110574049
Drug interaction 53.70 30.71 99 6156 500084 110082960
Cognitive disorder 52.87 30.71 42 6213 87469 110495575
Deafness neurosensory 52.66 30.71 20 6235 9599 110573445
Enuresis 52.01 30.71 16 6239 4080 110578964
Ileus paralytic 48.80 30.71 20 6235 11717 110571327
Product use in unapproved indication 48.56 30.71 89 6166 447288 110135756
Obesity 47.28 30.71 44 6211 113307 110469737
Sopor 47.09 30.71 28 6227 36518 110546526
Cyst 45.36 30.71 21 6234 16475 110566569
Prescribed overdose 44.47 30.71 38 6217 87543 110495501
Balance disorder 42.47 30.71 42 6213 116518 110466526
Leukopenia 42.38 30.71 47 6208 148744 110434300
Mitochondrial encephalomyopathy 41.70 30.71 7 6248 111 110582933
Intentional self-injury 41.37 30.71 26 6229 37403 110545641
Tremor 39.84 30.71 53 6202 202179 110380865
Osteopenia 36.64 30.71 20 6235 22189 110560855
Weight increased 32.95 30.71 73 6182 419571 110163473
Muscle rigidity 32.50 30.71 19 6236 24012 110559032
Salivary hypersecretion 32.42 30.71 17 6238 17404 110565640
Blood potassium increased 31.58 30.71 21 6234 33228 110549816
Deformity 31.29 30.71 14 6241 10146 110572898
Constipation 31.25 30.71 65 6190 357721 110225323

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N05AB03 NERVOUS SYSTEM
PSYCHOLEPTICS
ANTIPSYCHOTICS
Phenothiazines with piperazine structure
FDA CS M0016525 Phenothiazines
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014150 Antipsychotic Agents
MeSH PA D015259 Dopamine Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018492 Dopamine Antagonists
FDA EPC N0000175746 Phenothiazine
CHEBI has role CHEBI:35469 antidepressant
CHEBI has role CHEBI:35474 anxiolytic drug
CHEBI has role CHEBI:35476 antipsychotic agent
CHEBI has role CHEBI:37930 phenothiazine antipsychotic drug
CHEBI has role CHEBI:48561 dopaminergic antagonist
CHEBI has role CHEBI:50919 antiemetic

Related Drugs by ATC class:

N05AB Phenothiazines with piperazine structure 9 drugs
acetophenazinebutaperazinedixyrazinefluphenazineperazineprochlorperazinethiopropazatethioproperazinetrifluoperazine

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Nausea and vomiting indication 16932000
Schizophrenia indication 58214004 DOID:5419
Mixed anxiety and depressive disorder indication 231504006
Suicidal thoughts contraindication 6471006
Alcoholism contraindication 7200002
Organophosphate poisoning contraindication 8260003
Weight gain finding contraindication 8943002
Sinus tachycardia contraindication 11092001
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Senile dementia contraindication 15662003
Chronic disease of respiratory system contraindication 17097001
Myocardial infarction contraindication 22298006 DOID:5844
Glaucoma contraindication 23986001 DOID:1686
Orthostatic hypotension contraindication 28651003
Torsades de pointes contraindication 31722008
Parkinsonism contraindication 32798002
Hyperthyroidism contraindication 34486009 DOID:7998
Conduction disorder of the heart contraindication 44808001
Chronic heart failure contraindication 48447003
Bradycardia contraindication 48867003
Paralytic ileus contraindication 55525008 DOID:8442
Extrapyramidal disease contraindication 76349003
Hyperglycemia contraindication 80394007 DOID:4195
Chronic idiopathic constipation contraindication 82934008
Open-angle glaucoma contraindication 84494001 DOID:1067
Epilepsy contraindication 84757009 DOID:1826
Leukopenia contraindication 84828003 DOID:615
Stupor contraindication 89458003
Tardive dyskinesia contraindication 102449007
Prolonged QT interval contraindication 111975006
Acute disease of cardiovascular system contraindication 128487001
Bipolar affective disorder, current episode manic contraindication 191618007
Angina pectoris contraindication 194828000
Disease of liver contraindication 235856003 DOID:409
Metabolic syndrome X contraindication 237602007 DOID:14221
Hyperprolactinemia contraindication 237662005 DOID:12700
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Syncope contraindication 271594007
Anemia contraindication 271737000 DOID:2355
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Coma contraindication 371632003
At risk for aspiration contraindication 371736008
Angle-closure glaucoma contraindication 392291006 DOID:13550
Visual impairment contraindication 397540003
Breastfeeding (mother) contraindication 413712001
Myocardial ischemia contraindication 414795007 DOID:3393
Obesity contraindication 414916001 DOID:9970
Myocardial infarction in recovery phase contraindication 418044006
Congenital long QT syndrome contraindication 442917000
Carcinoma of female breast contraindication 447782002




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.21 Basic
pKa2 4.21 Basic
pKa3 2.21 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
D(2) dopamine receptor GPCR ANTAGONIST Ki 9.32 WOMBAT-PK CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 6.19 WOMBAT-PK
Potassium voltage-gated channel subfamily H member 2 Ion channel Ki 5.46 DRUG MATRIX
5-hydroxytryptamine receptor 1A GPCR Ki 6.07 WOMBAT-PK
5-hydroxytryptamine receptor 2A GPCR Ki 8.25 WOMBAT-PK
5-hydroxytryptamine receptor 2C GPCR Ki 6.88 WOMBAT-PK
5-hydroxytryptamine receptor 6 GPCR Ki 7.55 WOMBAT-PK
5-hydroxytryptamine receptor 7 GPCR Ki 7.64 WOMBAT-PK
Alpha-1A adrenergic receptor GPCR Ki 8 WOMBAT-PK
Alpha-2B adrenergic receptor GPCR Ki 6.98 WOMBAT-PK
D(3) dopamine receptor GPCR Ki 9.52 WOMBAT-PK
Histamine H1 receptor GPCR Ki 8.09 WOMBAT-PK
Muscarinic acetylcholine receptor M3 GPCR Ki 5.73 PDSP
Aldehyde oxidase Enzyme IC50 7.48 WOMBAT-PK
Alpha-2C adrenergic receptor GPCR Ki 7.07 WOMBAT-PK
D(4) dopamine receptor GPCR Ki 7.59 WOMBAT-PK
Retinal dehydrogenase 1 Enzyme IC50 6.28 CHEMBL
5-hydroxytryptamine receptor 7 GPCR ANTAGONIST Ki 7.60 IUPHAR
5-hydroxytryptamine receptor 6 GPCR ANTAGONIST Ki 7.80 IUPHAR
Pleiotropic ABC efflux transporter of multiple drugs Transporter IC50 5.85 CHEMBL

External reference:

IDSource
4017939 VUID
N0000146289 NUI
D00503 KEGG_DRUG
4017939 VANDF
C0031184 UMLSCUI
CHEBI:8028 CHEBI
CHEMBL567 ChEMBL_ID
D010546 MESH_DESCRIPTOR_UI
DB00850 DRUGBANK_ID
4748 PUBCHEM_CID
209 IUPHAR_LIGAND_ID
637 INN_ID
FTA7XXY4EZ UNII
8076 RXNORM
2271 MMSL
5261 MMSL
d00855 MMSL
001477 NDDF
387229007 SNOMEDCT_US
41147003 SNOMEDCT_US
FTA7XXY4EZ INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Perphenazine and Amitriptyline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0378-0042 TABLET, FILM COATED 4 mg ORAL ANDA 19 sections
Perphenazine and Amitriptyline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0378-0073 TABLET, FILM COATED 4 mg ORAL ANDA 19 sections
Perphenazine and Amitriptyline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0378-0330 TABLET, FILM COATED 2 mg ORAL ANDA 19 sections
Perphenazine and Amitriptyline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0378-0442 TABLET, FILM COATED 2 mg ORAL ANDA 19 sections
Perphenazine and Amitriptyline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0378-0574 TABLET, FILM COATED 4 mg ORAL ANDA 19 sections
Perphenazine HUMAN PRESCRIPTION DRUG LABEL 1 0591-4101 TABLET, FILM COATED 2 mg ORAL ANDA 20 sections
Perphenazine HUMAN PRESCRIPTION DRUG LABEL 1 0591-4102 TABLET, FILM COATED 4 mg ORAL ANDA 20 sections
Perphenazine HUMAN PRESCRIPTION DRUG LABEL 1 0591-4103 TABLET, FILM COATED 8 mg ORAL ANDA 20 sections
Perphenazine HUMAN PRESCRIPTION DRUG LABEL 1 0591-4104 TABLET, FILM COATED 16 mg ORAL ANDA 20 sections
Perphenazine HUMAN PRESCRIPTION DRUG LABEL 1 0603-5060 TABLET, FILM COATED 2 mg ORAL ANDA 19 sections
Perphenazine HUMAN PRESCRIPTION DRUG LABEL 1 0603-5061 TABLET, FILM COATED 4 mg ORAL ANDA 19 sections
Perphenazine HUMAN PRESCRIPTION DRUG LABEL 1 0603-5062 TABLET, FILM COATED 8 mg ORAL ANDA 19 sections
Perphenazine HUMAN PRESCRIPTION DRUG LABEL 1 0603-5063 TABLET, FILM COATED 16 mg ORAL ANDA 19 sections
Perphenazine HUMAN PRESCRIPTION DRUG LABEL 1 0781-8046 TABLET, FILM COATED 2 mg ORAL ANDA 19 sections
Perphenazine HUMAN PRESCRIPTION DRUG LABEL 1 0781-8047 TABLET, FILM COATED 4 mg ORAL ANDA 19 sections
Perphenazine HUMAN PRESCRIPTION DRUG LABEL 1 0781-8048 TABLET, FILM COATED 8 mg ORAL ANDA 19 sections
Perphenazine HUMAN PRESCRIPTION DRUG LABEL 1 0781-8049 TABLET, FILM COATED 16 mg ORAL ANDA 19 sections
Perphenazine HUMAN PRESCRIPTION DRUG LABEL 1 0904-6599 TABLET, FILM COATED 2 mg ORAL ANDA 19 sections
Perphenazine HUMAN PRESCRIPTION DRUG LABEL 1 0904-6600 TABLET, FILM COATED 4 mg ORAL ANDA 19 sections
Perphenazine HUMAN PRESCRIPTION DRUG LABEL 1 0904-6601 TABLET, FILM COATED 8 mg ORAL ANDA 19 sections
Perphenazine HUMAN PRESCRIPTION DRUG LABEL 1 21695-141 TABLET, FILM COATED 4 mg ORAL ANDA 18 sections
Perphenazine HUMAN PRESCRIPTION DRUG LABEL 1 21695-415 TABLET, FILM COATED 8 mg ORAL ANDA 18 sections
PERPHENAZINE Human Prescription Drug Label 1 23155-799 TABLET 2 mg ORAL ANDA 16 sections
PERPHENAZINE Human Prescription Drug Label 1 23155-800 TABLET 4 mg ORAL ANDA 16 sections
PERPHENAZINE Human Prescription Drug Label 1 23155-801 TABLET 8 mg ORAL ANDA 16 sections
PERPHENAZINE Human Prescription Drug Label 1 23155-802 TABLET 16 mg ORAL ANDA 16 sections
Perphenazine Human Prescription Drug Label 1 33342-448 TABLET 2 mg ORAL ANDA 14 sections
Perphenazine Human Prescription Drug Label 1 33342-449 TABLET 4 mg ORAL ANDA 14 sections
Perphenazine Human Prescription Drug Label 1 33342-450 TABLET 8 mg ORAL ANDA 14 sections
Perphenazine Human Prescription Drug Label 1 33342-451 TABLET 16 mg ORAL ANDA 14 sections